false 0001411690 0001411690 2022-11-29 2022-11-29 0001411690 us-gaap:CommonStockMember 2022-11-29 2022-11-29 0001411690 bngo:WarrantsToPurchaseCommonStockMember 2022-11-29 2022-11-29

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 29, 2022
Bionano Genomics, Inc
(Exact Name of Registrant as Specified in its Charter)

Delaware | 001-38613 | 26-1756290
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.)

9540 Towne Centre Drive, Suite 100 |  |
San Diego, California |  | 92121
(Address of Principal Executive Offices) |  | (Zip Code)

Registrant’s telephone number, including area code: (858) 888-7600
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, $0.0001 par value per share | BNGO | The Nasdaq Stock Market LLC
Warrants to purchase Common Stock | BNGOW | The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. | Other Events

Investor Presentation
On November 28, 2022, the Company issued a press release announcing a live webcast presentation and conference call to be held November 29, 2022 (the “Conference Call”). A presentation to accompany the Conference Call (the “Investor Presentation”) is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Information contained in the Investor Presentation may also be used by the Company in future meetings regarding the Company.

Item 9.01. | Financial Statements and Exhibits.

(d) Exhibits

Exhibit | Description
99.1 | Investor Presentation dated November 29, 2022.
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 29, 2022 | Bionano Genomics, Inc.
| By: | /s/ R. Erik Holmlin, Ph.D.
|  | R. Erik Holmlin, Ph.D.
|  | President and Chief Executive Officer (Principal Executive Officer)